About Event
Accelerate Therapeutic Efficacy & Delivery Potential of Exosomes & Extracellular Vesicle
Uniquely positioned as the most comprehensive biopharma forum in the field, the 7th Exosome-Based Therapeutic Development Summit brought together both established exosome leaders and emerging innovators. The event showcased the latest applications spanning CNS disorders to cancer, highlighted new trends in characterization and analytical development, and explored advances in purification, isolation technologies, and clinical-grade manufacturing. Key considerations for regulatory IND submissions and commercial filings were also front and center.
Attendees engaged directly with the leading players making the most significant strides in exosome research and development. The summit provided first-hand insights and actionable takeaways that helped participants accelerate their pipelines and stay at the forefront of this rapidly evolving field.
Key Clinical Updates From
Key Benefits of Attending
Achieve the scale and manufacturing excellence of your exosome products with GMP compliance and batch-to-batch consistency for commercial viability with insights from EXO Biologics, EverZom & NurExone Biologic
Advance your pipelines toward the clinic with fresh data and experience from leading exosome & EV developers on the path towards the first therapeutic approval, with insights from Direct Biologics, Rion, Aegle Therapeutics & Aruna Bio
Harness translational strategies & therapeutic innovations with relevant translational model case-studies to reinvigorate your pipeline with insights from EV Therapeutics, Diadem Biotherapeutics & Capricor Therapeutics
Establish robust and standardized analytical and characterization methods to unlock size, surface markers, andexosome isolation techniques with insights from Loyola University Chicago & Clemson University
Leverage exosomes & EVs as the delivery vehicle of choice for a variety of payloads with improved tropism, targeted delivery, and immunogenicity with insights from ShiftBio & AGS Therapeutics
Don't Just Take Our Word For It...
"I look forward to sharing the challenges in developing exosome-based therapeutics, in particular the biodistribution and targeted delivery of engineered exosomes/EVs"
Kuldeep Neote, Chief Executive Officer, Diadem Biotherapeutics
“This Exosome-Based Therapeutic Development Summit offers a collaborative environment to share knowledge in order to expedite clinical studies and potentially commercialization”
Jahan Jowharchi, Chief Technical Operations, Rion